NCT05170594

A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer

A Prospective Study of Bevacizumab Combined With Fluzoparib, Bevacizumab Combined With Chemotherapy or Fluzoparib Monotherapy in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: The Second Affiliated Hospital of Shandong First Medical University · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study was designed to explore the safety and efficacy of Bevacizumab combined with Fluzoparib, Bevacizumab combined with chemotherapy or Fluzoparib monotherapy in patients with platinum-resistant recurrent ovarian cancer.

Detailed description

This purpose of this study is to explore efficacy of Bevacizumab combined with Fluzoparib, Bevacizumab combined with chemotherapy or Fluzoparib monotherapy in patients with platinum-resistant recurrent ovarian cancer.Besides the efficacy,we focus on the safety and quality of life in the new treatments.

Conditions

• Ovarian Cancer

Interventions

Type	Name	Description
DRUG	Bevacizumab	Bevacizumab will be administered at 15mg/kg IV, every 3 weeks
DRUG	chemotherapy	The non-platinum chemotherapy regimen will be determined by the investigator.
DRUG	Fluzoparib	Fluzoparib will be administered orally continuously at 150mg bid until disease progression and toxicity becomes intolerable

Timeline

• Start date: 2021-12-24
• Primary completion: 2024-06-30
• Completion: 2024-06-30
• First posted: 2021-12-28
• Last updated: 2021-12-28

Locations

1 site across 1 country: China